Data from the REDEFINE-1 trial (NCT05567796) were recently presented in Türkiye, showcasing the efficacy of Novo Nordisk’s CagriSema in improving body composition among adults with obesity. This trial is pivotal as it not only highlights the potential of CagriSema as a therapeutic option but also reinforces the growing focus on body composition as a critical endpoint in obesity management.
The implications of these findings are significant for the pharmaceutical industry, particularly for B2B professionals involved in regulatory affairs, quality assurance, and clinical development. As obesity continues to be a global health crisis, the data from REDEFINE-1 could influence future regulatory submissions and shape market strategies for obesity treatments. Companies may need to revisit their portfolios to align with emerging evidence that prioritizes body composition improvements alongside weight loss.
Get started today with Solo access →
